logo
Plus   Neg
Share
Email

BioXcel Expands Collaboration With Nektar To Initiate New Clinical Program

BioXcel Therapeutics, Inc. (BTAI) and Nektar Therapeutics (NKTR) announced they are expanding the ongoing research collaboration into a new clinical partnership. The collaboration will clinically evaluate the combination of BTI's BXCL701, a small molecule immune-modulator, DPP 8/9 and FAP inhibitor; Nektar's NKTR-214, a CD122-biased agonist; and a checkpoint inhibitor as a potential therapy for pancreatic cancer.

BTI will be responsible for initiating and managing the clinical program. The primary objectives of the study are to evaluate safety and efficacy of the triplet combination of BXCL701, NKTR-214 and a checkpoint inhibitor for the treatment of patients with unresectable or metastatic pancreatic cancer.

BTI and Nektar Therapeutics initially announced a preclinical research collaboration in November 2017.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
SCARPA North America has recalled about 4,200 ski boots due to risk of fall. The company has recalled Maestrale RS and Maestrale Men's ski boots as its shell can crack, posing a fall hazard and risk of injury to the consumer. The recall involves the Fall 2017 Maestrale RS and Maestrale Men's Ski... Walt Disney's (DIS) Frozen 2, the sequel to its 2013 blockbuster, is expected to record a strong domestic opening of over $100 million this weekend. Frozen 2 will become the 10th animated film to debut with over $100 million and the first animated film outside the summer window to hit the mark. Frozen... Indonesia is exploring a total ban on the use of electronic cigarettes and vape products in the country due to healthcare concerns following the lung illness outbreak related to vaping in the U.S., according to reports. However, the South-East Asian country has not reported any cases of vaping-related illness. Chain-smoking Indonesia is the world's second largest tobacco market.
Follow RTT
>